IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.

IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.

Combined expression of costimulatory factors and proinflammatory cytokines stimulate effective immune-mediated tumor rejection in a variety of murine tumor models. Specifically, syngeneic tumor cells genetically modified to express B7.1 (CD80) have been shown to induce rejection of previously establ...

Detaylı Bibliyografya
Asıl Yazarlar:	Chan, L, Hardwick, N, Darling, D, Galea-Lauri, J, Gäken, J, Devereux, S, Kemeny, M, Mufti, G, Farzaneh, F
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2005

Benzer Materyaller

IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML
Yazar:: Chan, L, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Tumour cells expressing B7.1 costimulatory molecule: Are these better targets for NK cells?
Yazar:: GaleaLauri, J, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Fusagene vectors: A novel strategy for the expression of multiple genes from a single cistron
Yazar:: Gaken, J, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.
Yazar:: Gäken, J, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron
Yazar:: Gaken, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2.
Yazar:: Hirst, W, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells
Yazar:: Gaken, J, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Yazar:: Galea-Lauri, J, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

CYTOLOGICAL FEATURES WITH PROGNOSTIC-SIGNIFICANCE IN AML
Yazar:: Swirsky, D, ve diğerleri
Baskı/Yayın Bilgisi: (1983)

Mechanisms of response and resistance to AML therapies
Yazar:: Stoilova, B, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

The graft-versus-leukemia effect in AML
Yazar:: Sweeney, C, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML
Yazar:: Puram, Rishi V., ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Yazar:: Kersemans, V, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.
Yazar:: Gaken, J, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
Yazar:: Grimwade, D, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

High titre vectors for targeted expression of multiple genes
Yazar:: Darling, D, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Monocistronic high titre vectors for targeted expression of multiple therapeutic genes
Yazar:: Darling, D, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
Yazar:: Hoyle, C, ve diğerleri
Baskı/Yayın Bilgisi: (1989)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
Yazar:: Grimwade, D, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
Yazar:: Peniket, A, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.
Yazar:: Hong, D, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Suppression Of Aml1/ETO Via siRNA Mediated Gene Knockdown And Its Effects On FOXO3 AND c-Myc Expression In Aml t (8,21) Cells
Yazar:: Ong, Si Min
Baskı/Yayın Bilgisi: (2017)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Yazar:: Freeman, SD, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Yazar:: van Galen, Peter, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

The role of AML secretome and bone marrow microenvironment in establishment and maintenance of leukaemia initiating cells
Yazar:: Ren, X
Baskı/Yayın Bilgisi: (2023)

Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
Yazar:: Galea-Lauri, J, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Single cell RNA sequencing reveals AML immunoediting under pressure from engineered T cell therapy
Yazar:: Paulson, K, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

In vitro immune modulation by antibodies coupled to tumour cells.
Yazar:: Darling, D, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
Yazar:: Islam, M., ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
Yazar:: Bhatnagar, N, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Molecular characterization of the chromosome 9q deletion in AML.
Yazar:: Side, L, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
Yazar:: Chan, L, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.
Yazar:: Chan, L, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
Yazar:: Hills, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Dendritic cell/tumour fusions are more efficient at eliciting MHC class I-restricted Ag-specific CTL responses when compared to antigen-pulsed dendritic cells
Yazar:: Galea-Lauri, J, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins
Yazar:: Elegheert, J, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo.
Yazar:: Cai, Z, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Yazar:: Galea-Lauri, J, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

A polycistronic retroviral vector encoding hB7-1 (CD80) and hIL-2 for ex vivo cancer gene therapy.
Yazar:: Kuiper, M, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
Yazar:: Goh, Chermaine Yu Zhen
Baskı/Yayın Bilgisi: (2021)